Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia-Post hoc exploratory analyses of the COVID STEROID 2 trial.

Anders Granholm Marie Warrer Munch Nina Christine Andersen-RanbergSheila Nainan MyatraBharath Kumar Tirupakuzhi VijayaraghavanBalasubramanian VenkateshVivekanand JhaRebecka Rubenson WahlinStephan M JakobLuca CioccariMorten Hylander MöllerAnders Perner

Published in: Acta anaesthesiologica Scandinavica (2022)

We found no strong evidence for HTE with 12 versus 6 mg dexamethasone daily on days alive without life support or mortality at Day 90 in patients with COVID-19 and severe hypoxaemia, although these results cannot rule out HTE either.

Keyphrases

low dose
coronavirus disease
high dose
early onset
sars cov
clinical trial
physical activity
randomized controlled trial
combination therapy
double blind
placebo controlled